Synthesis of Rare Disease in RED OCEAN of Meta-analysis (MA)

An experience on MA of losartan for Marfan syndrome (MFS)

Yi-No Kang M.A.Ed



July 29, 2019


Assessment of Publication Trends of Systematic Reviews and Randomized Clinical Trials, 1995 to 2017

Joshua D. Niforatos, MD, MTS¹; Matt Weaver, MA, MS-LIS²; Michael E. Johansen, MD, MS³

¹Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio

JAMA Intern Med. 2019;179(11):1593-1594. doi:10.1001/jamainternmed.2019.3013

Figure 1. Published Systematic Reviews vs Randomized Clinical Trials, 1995-2017



²Cleveland Clinic Floyd D. Loop Alumni Library, Cleveland Clinic, Cleveland, Ohio

³Grant Family Medicine, OhioHealth, Columbus, Ohio



July 29, 2019

Meta-analysis Metastasis


Joshua D. Wallach, MS, PhD1


W Author Affiliations

¹Department of Environmental Health Sciences, Yale School of Public Health, and the Collaboration for Research Integrity and Transparency, Yale Law School, New Haven, Connecticut

JAMA Intern Med. 2019;179(11):1594-1595. doi:10.1001/jamainternmed.2019.2999


Although these trends indicate an alarming growth in the popularity of reviews across different specialties, rigorous systematic reviews and meta-analyses are still among the most informative research studies. The findings reported by Niforatos et al³ do not suggest that reviews should be abandoned or that more trials are necessary. Instead, they support efforts to prioritize more robust trials and reviews, including living reviews in which meta-analyses are available online and continuously updated as additional studies are identified, as well as prospective and individual patient-level metaanalyses. Priority should be given to reviews that are conducted by nonconflicted investigators, including metaanalytical experts and research librarians, who help formulate search terms, identify relevant databases, and minimize any search inadequacies. To help curtail the production (and publication) of redundant, biased, and conflicted reviews, peer reviewers and editors may need additional training to assess the quality of submitted manuscripts. Together, these efforts can help slow the meta-analysis metastasis.











Synthhesis of Rare Disease in RED OCEAN of Meta-analysis (MA) An experience on MA of losartan for Marfan syndrome (MFS)

Yi-No Kang M.A.Ed,





ORIGINAL ARTICLE

Progression of Aortic Dilatation and the Benefit of Long-Term β-Adrenergic Blockade in Marfan's Syndrome

Jennifer Shores, Kenneth R. Berger, Edmond A. Murphy, and Reed E. Pyeritz





European Heart Journal (2013) 34, 3491–3500 doi:10.1093/eurheart/eht334 FASTTRACK CLINICAL RESEARCH

Congenital heart disease




Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial

Maarten Groenink^{1,2,3*}, Alexander W. den Hartog^{1,2†}, Romy Franken^{1,2†}, Teodora Radonic⁴, Vivian de Waard⁵, Janneke Timmermans⁶, Arthur J. Scholte⁷, Maarten P. van den Berg⁸, Anje M. Spijkerboer³, Henk A. Marquering^{3,9}, Aeilko H. Zwinderman^{1,4}, and Barbara J.M. Mulder^{1,2}

Losartan Added to β -Blockade Therapy for Aortic Root Dilation in Marfan Syndrome: A Randomized, Open-Label Pilot Study

Hsin-Hui Chiu, MD^{a,b}, Mei-Hwan Wu, MD, PhD^{b,*} Mei-Hwan Wu, MD, PhD^b, Shuenn-Nan Chiu, MD, PhD^b, Chun-An Chen, MD^b, Ming-Tai Lin, MD, PhD^b, Fu-Chang Hu, MS^c







ORIGINAL ARTICLE

Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome


Ronald V. Lacro, M.D., Harry C. Dietz, M.D., Lynn A. Sleeper, Sc.D., Anji T. Yetman, M.D., Timothy J. Bradley, M.B., Ch.B., Steven D. Colan, M.D., Gail D. Pearson, M.D., Sc.D., E. Seda Selamet Tierney, M.D., Jami C. Levine, M.D., Andrew M. Atz, M.D., D. Woodrow Benson, M.D., Ph.D., Alan C. Braverman, M.D., et al., for the Pediatric Heart Network Investigators*




Synthesized evidence on ARB for MFS



Story for today: MA of a rare disease (MFS)



Story for today: MA of a rare disease (MFS)
















Story for today: MA of a rare disease (MFS)



Reflection: RIGHT

- Keep RIGOUR in research
- Keep clinical INSIGHT in research
- O Just GO ahead
- Just HUG comments from reviewers
- Wait for my TIME to come

Q&A

Thanks for your listening



Contacts



